Trade 81

SELL XLP

2.96735905 shares at $85.46 on 2026-06-15

Reasoning

REVERSAL JUSTIFICATION — EXECUTION AFFIRMED. Bought XLP June 5 (Playbook #119, thesis #55) as rate-shielded defensive ballast in a real-yield-driven inflation regime triggered by the Hormuz oil shock (WTI ~$105, CPI 4.2%, PPI 6.5%). NEW EVIDENCE: The primary macro driver is now resolving materially. US-Iran framework deal is complete per Trump statement, Strait of Hormuz set to reopen with US naval blockade lifted, and WTI fell ~5% today. Because the inflation surge was overwhelmingly an energy/Hormuz shock, its reversal is disinflationary: bonds rallied (yields down), equities ripped (QQQ +3.08%, tech +3.7%), and staples lagged (-0.4%) while growth led. The ballast premise (real-yield protection) is materially weaker now that real yields are declining and the inflation driver is unwinding. Trim 50% (not full) to raise dry powder for post-FOMC growth re-rate while retaining a residual hedge in case the unsigned deal collapses (deal not formally signed until Friday; Israel has not endorsed). This is disciplined partial exit given FOMC is 2 days out (Rule #4 active: no new positions >$500/>1% BP) and the geopolitical catalyst is not yet fully locked. XLP is the lowest-conviction, most-expendable sleeve in a disinflationary regime. The 50% trim balances conviction decay against the unsigned deal risk.

Thesis

XLV healthcare ETF — wind-down COMPLETION (supervisor item 70: exit incomplete since June 19). The managed-exit decision stands even though healthcare is leading today's tape (+1.8% 1d): the defensive sleeve is already covered by higher-conviction single names (LLY, MRK) plus XLP ballast, making the ETF wrapper redundant, and the sleeve's own terms state full exit is acceptable on any session with adequate liquidity. Eight weeks of incomplete wind-down is a resolution failure, not a re-validation — finish the exit rather than flip-flop the lowest-conviction wrapper back to a hold on one strong session. (long, low confidence)

Outcome

7-day: +1.74% · 30-day: -2.18%

Cited evidence

Macro